Skip to main content
Leslie Popplewell, MD, Oncology, Newnan, GA, City of Hope Atlanta

LeslieLPopplewellMD

Oncology • Newnan, GA

Hematologic Oncology

Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

Request Appointment

Overview of Dr. Popplewell

Dr. Leslie Popplewell is an oncologist in Newnan, GA and is affiliated with City of Hope Atlanta. She received her medical degree from University of Louisville School of Medicine and has been in practice 25 years. She is one of 36 doctors at City of Hope Atlanta who specialize in Oncology. She has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
  • Temple University Hospital
    Temple University HospitalResidency, Internal Medicine, 1992 - 1995
  • University of Louisville School of Medicine
    University of Louisville School of MedicineClass of 1992

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2023 - 2026
  • CA State Medical License
    CA State Medical License 1998 - 2025
  • GA State Medical License
    GA State Medical License 2023 - 2024
  • AZ State Medical License
    AZ State Medical License 2002 - 2017
  • PA State Medical License
    PA State Medical License 1993 - 1995

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma  
    Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
  • CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET  
    David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Abstracts/Posters

  • CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma
    Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
    Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
    Leslie L. Popplewell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • KOCO 5’S Zach Rael Donates Stem Cells to Try to Save a Cousin’s Life
    KOCO 5’S Zach Rael Donates Stem Cells to Try to Save a Cousin’s LifeJuly 17th, 2020
  • Implant-Associated Cancers: A Look Beyond Breast Implant-Associated Anaplastic Large Cell Lymphoma
    Implant-Associated Cancers: A Look Beyond Breast Implant-Associated Anaplastic Large Cell LymphomaSeptember 16th, 2019
  • City of Hope Awarded Lymphoma Specialized Programs of Research Excellence (SPORE) Grant from National Cancer Institute
    City of Hope Awarded Lymphoma Specialized Programs of Research Excellence (SPORE) Grant from National Cancer InstituteFebruary 21st, 2019
  • Join now to see all

Hospital Affiliations

Dr. Leslie Popplewell, Dr. Leslie Popplewell, MD, Dr. L Popplewell, Dr. Leslie L Popplewell